Specific siRNA-mediated silencing of cortactin, or treatment with cirmtuzumab, could inhibit the capacity of Wnt5a to enhance CXCL12-directed CLL-cell migration. This evidence concerns the gene CXCL12 and B-cell chronic lymphocytic leukemia.